

Performance Against Delivery Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
15/SC/0311	181166	CARD 4677 VEST III PMS	Number Agreed	15	15	Date Agreed	31/01/2017	15	31/01/2017	15	Recruitment Finished
12/NW/0367	104793	PLUTO	Number Agreed	0	0	Date Agreed	31/01/2017	0	01/02/2017	0	Recruitment Finished
16/NW/0262	200188	RESP 5664	Number Agreed	1	1	Date Agreed	10/03/2017	3	10/03/2017	3	Recruitment Finished
15/SC/0242	173490	HAEM 4448	Number Agreed	1	1	Date Agreed	30/03/2021	0	13/03/2017	0	Recruitment Finished
16/LO/0055	179500	OPHT 4645	Number Agreed	8	8	Date Agreed	24/03/2017	8	30/03/2017	8	Recruitment Finished
15/SC/0409	183061	OPHT 4170 (AMD)	Number Agreed	8	8	Date Agreed	01/06/2017	8	07/04/2017	8	Recruitment Finished
13/LO/1081	132715	PROSPER: MDV3100-14	Number Agreed	6	6	Date Agreed	30/06/2017	9	23/03/2017	10	Recruitment Finished
15/LO/2045	193136	CHIL 5229 SMT C1100 in Ambulatory Boys with DMD	Number Agreed	2	2	Date Agreed	10/02/2017	2	10/02/2017	2	Recruitment Finished
16/SC/0161	186322	GO29438 PhaseIII?Study-Atezolizumab?with?chemotherapy?in?Stage?IV?Non-Squamous	Number Agreed	4	4	Date Agreed	31/07/2017	5	20/04/2017	5	Recruitment Finished
15/LO/1236	183416	A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis	Number Agreed	1	1	Date Agreed	31/05/2017	0	21/04/2017	0	Recruitment Finished
16/SC/0018	191267	Study of CTX 4430 in Cystic Fibrosis Patients	Number Agreed	2	2	Date Agreed	15/05/2017	3	16/05/2017	3	Recruitment Finished
16/ES/0001	193859	GAST 5634	Number Agreed	3	3	Date Agreed	31/08/2017	1	22/05/2017	1	Withdrawn By Host
16/LO/1612	201997	Follow-up Study for Patients who Completed Study ALX0681-C301	Number Agreed	1	1	Date Agreed	30/11/2017	1	08/06/2017	1	Recruitment Finished
15/EM/0437	184390	COLUMBUS-AMD	Number Agreed	3	3	Date Agreed	30/06/2017	3	09/06/2017	3	Recruitment Finished
14/YH/1263	162807	CRIT 3719 (Intravascular glucose monitoring system)	Number Agreed	5	5	Date Agreed	30/06/2016	3	05/04/2017	3	Withdrawn By Sponsor
15/LO/1441	186018	HAEM 4790 (ALX0681-C301)	Number Agreed	3	3	Date Agreed	30/11/2017	1	08/06/2017	1	Recruitment Finished
16/EE/0011	194393	Phase III Otonomy Study 104-201508	Number Agreed	1	1	Date Agreed	30/06/2017	2	21/07/2017	2	Recruitment Finished
14/EM/0130	149751	NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy	Number Agreed	3	3	Date Agreed	31/08/2017	6	04/09/2017	6	Recruitment Finished

Performance Against Delivery Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
16/EE/0243	207331	A 6 Month Multicentre Phase 3, Open-Label extension Safety Study of OTO-104	Number Agreed	1	1	Date Agreed	30/11/2017	5	06/09/2017	5	Recruitment Finished
15/SC/0456	174561	CANC - 4254 - Anti-Pd-L1 Antibody (MPDL3280A) in Pediatric and Young Adult	Number Agreed	2	2	Date Agreed	31/10/2018	1	29/09/2017	1	Recruitment Finished
15/LO/2098	182147	INTEREST: FP-1201-lyo for the treatment of ARDS	Number Agreed	6	6	Date Agreed	31/12/2017	9	11/12/2017	9	Recruitment Finished
17/NW/0223	219119	Evaluation of PKU explore	Number Agreed	1	1	Date Agreed	31/12/2017	3	27/11/2017	3	Recruitment Finished
15/LO/0743	179335	HEPA 4444 (Hep B)	Number Agreed	4	4	Date Agreed	28/08/2018	3	18/09/2017	3	Withdrawn By Sponsor
14/EM/0215	152549	NCRN - 3109 Veliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breas	Number Agreed	1	1	Date Agreed	30/11/2017	1	30/11/2017	1	Recruitment Finished
13/SC/0173	108971	VIABLE	Number Agreed	6	6	Date Agreed	01/06/2017	15	07/10/2017	15	Recruitment Finished
16/EM/0408	211983	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	3	3	Date Agreed	31/12/2017	5	10/04/2017	5	Recruitment Finished
16/EE/0325	204922	Venetoclax (ABT-199) in relapsed/refractory CLL (M15-550)	Number Agreed	4	4	Date Agreed	01/07/2018	3	20/12/2017	3	Recruitment Finished
15/LO/0141	169126	OPHT 3845	Number Agreed	4	4	Date Agreed	31/12/2018	0	18/10/2017	0	Withdrawn By Host
16/SC/0542	208245	OMASPECT	Number Agreed	1	1	Date Agreed	31/01/2018	2	20/11/2017	2	Withdrawn By Sponsor
17/LO/0017	213632	Open-label Extension Study for Participants with Prostate Cancer	Number Agreed	2	2	Date Agreed	31/10/2017	2	01/10/2017	2	Recruitment Finished